Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P31749 (
AKT
)
22,954
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Estrogen receptors (ERalpha and ERbeta) are estrogen-regulated transcription factors that play important roles in the development and progression of breast cancer. The biological function of ERs has been shown to be modulated by ER-interacting proteins. However, the ER-interacting proteins that not only activate MAPK and
AKT
, two important growth regulatory protein kinases, but also increase growth related estrogen-responsive gene expression remain unknown. Here, we report that
hematopoietic PBX-interacting protein
(
HPIP
) interacts both with ERalpha and with ERbeta, and increases ERalpha target gene expression through activation of MAPK and
AKT
and enhanced ERalpha phosphorylation. ERbeta inhibits ERalpha target gene expression, possibly by competition of ERbeta with ERalpha for binding to
HPIP
, and by a decrease in available ERalpha for
HPIP
binding through the interaction of ERbeta with ERalpha. Furthermore,
HPIP
increases breast cancer cell growth. These data suggest that
HPIP
may be an important regulator in ER signaling and that the relative ratio of ERbeta to ERalpha may be important for
HPIP
function.
...
PMID:The estrogen receptor-interacting protein HPIP increases estrogen-responsive gene expression through activation of MAPK and AKT. 1830 41